Navigation Links
ACE Inhibitor as Effective as More Expensive Blood Pressure Drug
Date:3/31/2008

Study focused on more than 17,000 people with coronary artery disease or diabetes

MONDAY, March 31 (HealthDay News) -- Treatment with an ACE inhibitor drug was as effective in reducing deaths, heart attacks and stroke in a high-risk group of patients as a newer and more expensive angiotensin-receptor blocker (ARB) drug, a large international study has found.

The study of more than 17,000 people with coronary artery disease or diabetes found no major differences between those treated with the widely used ACE inhibitor ramipril (Altace) and those given the ARB telmisartan (Micardis).

"This is the first study in such a population that shows ACE inhibitors are as effective as ARBs," said study leader Dr. Salim Yusuf, a professor of medicine at McMaster University, in Hamilton, Ontario, Canada.

The finding might reduce the use of ARBs for such high-risk people, he said. "Even before the trial, many physicians have used ACE inhibitors as a first choice," Yusuf said. "I believe it will have an impact on practice."

The findings were to be presented Monday at the American College of Cardiology annual meeting in Chicago, and will be published in the April 10 issue of the New England Journal of Medicine.

Both classes of drugs are prescribed to lower blood pressure. But they act in different ways to block the activity of angiotensin, a molecule that narrows blood vessels.

"The main value of ARBs as monotherapy in patients with cardiovascular disease is, in my opinion, as a substitute for an ACE inhibitor in a patient who cannot tolerate the ACE inhibitor because of cough," said Dr. John J.V. McMurray, a professor of medical cardiology at the University of Glasgow in Scotland, who wrote an editorial accompanying the journal report.

"ACE inhibitors have never been tested in an outcome study in this patient population, and an ACE inhibitor and ARB have never been compared in this patient population," McMurray noted.

During a median follow-up time of 56 months, the incidence of deaths and adverse events was almost identical in the two groups -- 16.5 percent for those taking ramipril and 16.7 percent in the telmisartan group. It was also about the same in a group prescribed both medications, 16.3 percent, but there was a higher incidence of side effects such as abnormally low blood pressure and kidney problems among those taking the combination drug therapy.

ARBs still have a place in treatment of high-risk people such as those in the study, Yusuf said. "About 20 to 30 percent of people who take ACE inhibitors have side effects that make them stop," he said. The most common side effect is cough.

"On the other hand, ARBs seem to be valuable when added to an ACE inhibitor in patients with heart failure," McMurray said. The new study group did not include people with heart failure.

Switching from an ARB to an ACE inhibitor can reduce the cost of medical care, Yusuf said. Pill for pill, the cost of an ARB is about 20 percent higher than for an ACE inhibitor in Canada, he said.

More information

Learn more about ACE inhibitors, ARBs and other drugs for high blood pressure from the American Heart Association.



SOURCES: Salim Yusuf, M.D., professor, medicine, McMaster University, Hamilton, Ontario; John J.V. McMurray, M.D., professor, medical cardiology, University of Glasgow, Scotland; March 31, 2008, presentation, American College of Cardiology annual meeting, Chicago; April 10, 2008, New England Journal of Medicine


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
2. Late Use of Aromatase Inhibitor Still Effective Against Breast Cancer
3. Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients
4. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
5. S*BIOs Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders
6. Silencing small but mighty cancer inhibitors
7. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
8. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
9. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
10. Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients
11. Guardian Survey: Despite Perceived Effectiveness, Most Employees Who Participate in Wellness Programs Do Not Stay Committed
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
ACE Inhibitor as Effective as More Expensive Blood Pressure Drug
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... Lake Park ... smiles by using Invisalign® in Lutz, FL. With the help of this ... and aesthetics with fewer potential complications, more discretion and less pain. , Drs. ...
(Date:4/25/2017)... ... April 25, 2017 , ... As Spring reignites vigilance ... research related to Zika virus during pregnancy, as well as other prenatal exposures ... science. , The Teratology Society is an international and multidisciplinary ...
(Date:4/25/2017)... ... , ... Saad B. Chaudhary, MD is committed to providing the highest quality of spine care ... on preventative care with all my patients to alleviate possible future issues. I am pleased ... contact my office and my trained staff will assist you in any way possible.” , ...
(Date:4/25/2017)... Hollywood, Fl (PRWEB) , ... April 25, 2017 , ... ... than Memorial Regional Hospital, according to a special report in the May issue of ... Hospital its highest quality ranking for results achieved during and after coronary bypass ...
(Date:4/24/2017)... ... April 24, 2017 , ... Emmanuel College ... nursing professionals advance their careers. Beginning in the fall of 2017, Emmanuel’s program will ... in as few as 16 months and for as little as $14,528. These changes ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 NeuroVive ... ("NeuroVive") today announced positive preclinical results demonstrating ... compound for non-alcoholic steatohepatitis (NASH), in an ... NV556 has previously shown similar ... model. Today, NeuroVive,s scientists present novel data ...
(Date:4/19/2017)... 2017  IRIDEX Corporation (Nasdaq: IRIX ) ... the first quarter 2017 after the close of trading ... will host a corresponding conference call beginning at 2:30 ... interested in listening to the conference call may do ... (703) 326-3030 for international callers, using conference ID: 92158987.  ...
(Date:4/19/2017)... 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and other unmet ... previously announced underwritten public offering of 23,625,084 shares ... price of $2.00 per share, before deducting underwriting ... by Sorrento.  The net proceeds to Sorrento from ...
Breaking Medicine Technology: